ProQR Therapeutics N.V.

ProQR Therapeutics N.V. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. This stock has a reasonable momentum. ProQR Therapeutics N.V. is not a good value stock. ProQR Therapeutics N.V. is not a good growth stock. ProQR Therapeutics N.V. is not very popular among insiders. ProQR Therapeutics N.V. is a mediocre stock to choose.

ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development...

News

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

Globe Newswire LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies...\n more…

Reviewing ProQR Therapeutics (NASDAQ:PRQR) and OptiNose (NASDAQ:OPTN)

Ticker Report ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) and OptiNose (NASDAQ:OPTN - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two...\n more…

ProQR Therapeutics (NASDAQ:PRQR) versus Moleculin Biotech (NASDAQ:MBRX) Financial Analysis

Zolmax Moleculin Biotech (NASDAQ:MBRX - Get Free Report) and ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the...\n more…

PRQR Stock Earnings: ProQR Therapeutics Beats EPS, Misses Revenue for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nPRQR stock results show that ProQR Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second...\n more…

ProQR Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St ProQR Therapeutics ( NASDAQ:PRQR ) Second Quarter 2024 Results Key Financial Results Revenue: €6.46m (up 420% from 2Q...\n more…

ProQR Announces Second Quarter 2024 Operating and Financial Results

Globe Newswire AX-0810 program targeting NTCP for cholestatic diseases and AX-1412 program targeting B4GALT1 for cardiovascular diseases advancing to the clinic in late 2024/early 2025 with translational data and...\n more…